DiaMedica Therapeutics (NASDAQ:DMAC) Receives New Coverage from Analysts at Craig Hallum

Craig Hallum began coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report issued on Wednesday, Marketbeat reports. The firm set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective indicates a potential upside of 216.21% from the company’s current price.

Separately, Oppenheimer reissued an “outperform” rating and set a $6.00 price objective (down previously from $7.00) on shares of DiaMedica Therapeutics in a research note on Thursday, March 21st.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ:DMAC opened at $2.53 on Wednesday. The company has a 50 day moving average of $2.80 and a 200-day moving average of $2.69. DiaMedica Therapeutics has a one year low of $1.53 and a one year high of $4.75. The stock has a market cap of $96.03 million, a price-to-earnings ratio of -4.08 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Equities research analysts anticipate that DiaMedica Therapeutics will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DMAC. Avantax Advisory Services Inc. bought a new position in DiaMedica Therapeutics in the fourth quarter valued at approximately $36,000. Stonebridge Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the third quarter valued at approximately $52,000. Finally, Paragon Associates & Paragon Associates II Joint Venture lifted its stake in DiaMedica Therapeutics by 6.4% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after buying an additional 30,000 shares in the last quarter. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.